Cambridge Investment Research Advisors Inc. Buys 6,722 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Cambridge Investment Research Advisors Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 51.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,726 shares of the company’s stock after buying an additional 6,722 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Intellia Therapeutics were worth $140,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Ensign Peak Advisors Inc increased its holdings in shares of Intellia Therapeutics by 2.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock worth $457,000 after buying an additional 1,100 shares during the last quarter. Virtus ETF Advisers LLC increased its holdings in shares of Intellia Therapeutics by 47.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,242 shares of the company’s stock worth $61,000 after buying an additional 1,692 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Intellia Therapeutics by 28.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,148 shares of the company’s stock worth $95,000 after purchasing an additional 1,808 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Intellia Therapeutics during the 4th quarter worth about $25,000. Finally, Jones Financial Companies Lllp boosted its stake in shares of Intellia Therapeutics by 140.9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after purchasing an additional 2,280 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Wedbush reissued a “neutral” rating and issued a $7.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 16th. Canaccord Genuity Group lowered their price objective on shares of Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating for the company in a research report on Tuesday, June 3rd. Guggenheim lowered their price objective on shares of Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, May 12th. Chardan Capital reaffirmed a “buy” rating and issued a $68.00 price target on shares of Intellia Therapeutics in a research report on Friday, May 9th. Finally, Citigroup lowered their price target on shares of Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating for the company in a research report on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.37.

Intellia Therapeutics Price Performance

NASDAQ:NTLA opened at $11.95 on Tuesday. The firm has a market capitalization of $1.24 billion, a P/E ratio of -2.28 and a beta of 2.21. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $28.18. The company’s fifty day moving average price is $9.06 and its 200-day moving average price is $9.32.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.16. Intellia Therapeutics had a negative net margin of 1,154.10% and a negative return on equity of 56.06%. The firm had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. During the same quarter in the prior year, the business earned ($1.12) earnings per share. The business’s quarterly revenue was down 42.6% compared to the same quarter last year. Equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.